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Activity in Tissue 
SEIICH! IZAKI, M.D., PH.D., SANFORD M. GOLDSTEIN, M.D., KIMIE FUKUYAMA, M.D. , PH.D., AND 
WILLIAM L. EpSTEIN, M.D. 
Department of Dermatology, University of California, San Francisco, California, U.S.A. 
Patterns of fibrin deposition were investigated by im-
tnunofluorescence microscopy in livers of thymus intact 
(TI) and athymic (AT) mice infected with Schistosoma 
tnansoni. Thrombin and fibrinolysis inhibitor activity in 
tissue extracts also were measured. In TI mice fibrin was 
detected perivascularly by 6 weeks after infection and 
at 8 weeks it was found over the granulomas as they 
developed. Fibrin was cleared from the center of granu-
IOIIlas by 10 weeks. Thrombin inhibitor activity in-
creased at 4 to 6 weeks but declined below control levels 
later as granulomas formed. Fibrinolysis inhibitor activ-
ity, on the other hand, peaked at 9 to 12 weeks after 
infection. In AT mice extensive fibrin deposition was 
detected in the liver throughout the period when smaller 
and incomplete granulomas developed. Central clearing 
did not occur. Thrombin inhibitor activity greatly in-
creased by 8 weeks after infection but fibrinolysis inhib-
itor activity remained unchanged. These findings sug-
gest that fibrin deposition and fibrinolysis are orderly 
events regulated in the lesions by proteinases and their 
inhibitors and this seems to be a general tissue reaction 
in the early stage of chronic granuloma formation. Since 
local clearance of fibrin in vivo and fibrinolysis inhibitor 
activity from tissue extracts studied in vitro are more 
evident in TI mice than in AT mice, it appears that T cell 
function is important in modulating the tissue response 
during granulomatous inflammation. 
The clotting system is activated at sites of tissue damage by 
various stimuli [1 ,2], such as irritants [3], antigen-antibody 
complexes [4] and cell mediated hypersensitivity [5-7], and use 
of anticoagulants has been shown to inhibit the subsequent 
tissue response [3,4,6,7]. Several mechanisms are known by 
which the coagulation process participates in inflammations. 
Fihrinopeptide B split in fibrin formation was found to be 
c hemotactic to neutrophils and monocytes [8]. It has been 
postulated that a framework of fibrin acts to support cellular 
infiltration and capillary propagation [9]. In Masugi nephritis, 
continuous ingestion of fibrin by endothelial and intercapillary 
cells of glomeruli resulted in cell necrosis [5]. 
The fibrinolytic process also contributes to inflammatory 
reactions by degrading fibrin. A variety of cell types seem to 
participate in this system. Kwaan and Astrup [10], utilizing 
implanted plasma clots, reported that plasminogen activator of 
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capillary endothelium was responsible for removal of fibrin. 
Ryan, Nishioka and Dawber demonstrated a similar mechanism 
immediately after deep dermal injury [11]. On the other hand, 
Dvorak et al [12] found that plasminogen activator was present 
in basophil plasma membrane. They suggested that this enzyme 
accounts for the limited amount of fibrin found in cutaneous 
basophil hypersensitivity [13], contrast to the heavy fibrin 
deposition observed in classic delayed hypersensitivity [5,13]. 
It is believed that similar mechanisms are involved in granu-
lomatous hypersensitivity. In vitro studies have shown that T-
cell activated macrophages secrete plasminogen activator 
[14,15] and that an enzyme from polymorphonuclear leukocytes 
can degrade fibrin into small peptides different from the fibrin 
degradation products by plasmin [16]. However, in vivo animal 
models to investigate grannulomatous hypersensitivity in skin 
are not yet available. 
Recently, we measured inhibitor activity to clotting and 
fibrinolytic enzymes in tissue during granulomatous inflamQ1a-
tion in liver of schistosome infected mice [17]. Antithrombin 
activity increases before formation of the granulomas and an-
tifibrinolytic activity increases along with granuloma develop-
ment. These findings indirectly demonstrate that the coagula-
tion and fibrinolytic systems are involved in this type of inflam-
mation as well. In the present study, we used immunofluores-
cence microscopy to directly demonstrate kinetics of fibrin 
deposition . Both thymus intact and athymic mice infected with 
Schistosoma mansoni were used in order to correlate patterns 
of fibrin deposition with cellular composition of the granulomas 
which occur in the 2 types of mice [18]. Clotting and clot lysis 
time assays were also performed to quantify inhibitor activities 
in tissue extracts. 
MATERIALS AND METHODS 
Experimental Animals 
Forty thumus intact (TI) and 20 athymic (AT) mice with 16 litter-
mates (LM) , all from the BALB/c strain, were infected with 50 cercariae 
of Schistosoma mansoni freshly hatched from snails. AT and LM were 
kept in temperature controlled, sterilized ftIter top cages in isolated 
quarters. At specified weeks after infection, mice were sacrificed after 
bleeding from the femoral artery under anesthesia. Noninfected mice 
of 1'1, AT and LM were used as controls. Livers were removed, diced 
and quick-frozen in liquid nitrogen, and stored at - 20°C. 
In.direct Immunofluorescence Technique 
Antigen: Mouse plasma (20 ml purchased from Pel-Freez Biologicals 
Inc., Rogers, Ark.) was diluted with 100 ml of 0.15 M NaCI solution and 
clotted by bovine thrombin (10 NIH U/ml in final concentration of 
Pentex thrombin, lot 10, Miles Laboratories Inc., Elkhart, Ind.) in the 
presence of 2.5 mM CaCh and 10 ffiM e-amino-n-caproic acid (lot 37C-
0317, Sigma Chern. Corp., St. Louis, MO). This was poured over filter 
paper and 95 mg of white clot was collected. After washing in 0.15 M 
NaCI extensively, fibrin was homogenized with a glass homogenizer in 
distilled water and lyophilyzed. 
Rabbit antimouse fibrin/ fibrinogen (anti-Fib) serum: A rabbit was 
injected subcutaneously with 8 mg of lyophilyzed powder suspended in 
1 ml of 0.15 M NaCI mixed with 1 ml of BacTO incomplete adjuvant 
(lot 474449, Difco Laboratories, Detroit, Mich.) in the presence of 10 
mg of sterilized powder of Mycobacterium tuberculosis (H37Ra, lot 
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595896 from Difcco Lab.) Three weeks later the same antigen without 
the powder of M. tuberculosis was re-injected. Four weeks after the 
fust injection blood was drawn from a marginal ear vein and serum was 
separated. The rabbit serum was absorbed with cross-linked mouse 
serum-agar. Rabbit antiserum after absorption yielded a single precip-
itin line reacting with mouse plasma, but not with mouse serum. 
Microscopy. Sections of 4 /lm thick were cut and washed with 0.02 M 
phosphate buffered 0.14 M NaCl, pH 7.2 at 4°C for 2 hr. They were 
reacted with the anti-Fib serum diluted by 1:100, and stained with 
FITC labeled goat antirabbit IgG (lot 2226 MOOIAI, Hyland Div., 
Travenol Laboratories Inc., Los Angeles, Ca.). The sections were ob-
served and photographed with a Zeiss fluorescence microscope using a 
B-12G excitor ftiter and barrier ftiters 44, 50 and 65. Immunological 
specificity was confumed by use of unlabeled goat antirabbit IgG and 
FITC labeled goat antimouse IgG for the poststaining. Adjacent sec-
tions were fixed in 10% formalin and stained with hematoxylin and 
eosin. Cell types appearing in the granulomas were examined with a 
Zeiss photomicroscope. 
Quanntitatiue Inhibitor Assays 
Frozen livers were homogenized with a glass homogenizer in 9 times 
volume of 0.05 M Tris-HCl buffer with 0.1 M NaCl, pH 7.5 (tri-saline), 
at 4°C. Supernatant was separated by centrifugation at 20,000 g for 20 
min. 
Clotting time assay: Fibrinogen solution containing 0.65 mg of 
clottable fibrinogen (bovine fibrinogen 65% clottable, lot 80, or 95% 
clottable, lot 22, Miles Laboratories Inc., Elkhart, Ind.) in 0.2 ml of 0.05 
M borate buffer with 0.1 M NaCl, pH 7.5 (borate-saline) was 
mixed with 0.2 ml of serially diluted tissue extracts and placed in a 
water bath at ·25°C. To this: 0.35 NIH U thrombin (lot 10 and 15 were 
used) in 0.1 ml borate-saline was added 1 min later. Time required for 
formation of a fibrin clot was measured: Use of tris-saline instead of a 
tissue extract gave clotting time of 30 seconds. Inhibitor activity was 
expressed as the thrombin unit which caused 50% inhibition [17]. In 
order to evaluate further if the tissue extract contained heparin and 
serum antithrombin III (heparin cofactor) which also affect clotting 
t ime, we examined effects of protamine sulfate (a heparin neutralizer) 
and heparin [19,20]. A solution (0.1 ml) of heparin sodium (Liquaemin 
sodium, lot 783678811, Organon, Inc. , W. Orange, NJ), protamine sulfate 
(lot R3687, Mann Research Laboratories Inc., New York, NY) or tris-
saline was added to the fibrinogen and tissue extract mixture before 
thrombin addition. 
Effects of protamine sulfate and heparin on the clotting time are 
summarized in Table I. Heparin prolonged clotting time from 32 to 90 
seconds at a concentration of 0.02 U and 2.5 /lg of protamine sulfate 
inhibited this action. The same dose protamine sulfate, however, did 
not shorten the clotting time measured in tissue extracts. Since 0.0002 
U of heparin did not show prolongation of the clotting time, we used 
this dose for unmasking antithrombin III activity. Addition of heparin 
with and without protamine sulfate at this dose had no effect on the 
clotting time measured with 2 samples prepared from livers of TI mice 
5 weeks after infection. 
Clot lysis time assay: Borate-saline containing 1.6 mg/0.5 ml of 
clottable fibrinogen (65% clottable bovine fibrinogen) was used as the 
source of plasminogen and fibrinogen. This was mixed with 0.3 ml of 
serially diluted tissue samples and kept at 37°C in a water bath. After 
1 min, 0.1 ml of 5 Ploug U of urokinase (lot 601990, 801138 and 802682, 
Calbiochem, San Diego, Ca.) was added, and 30 seconds later 0.1 ml of 
4 NIH U thrombin was also added. The mixture was clotted and lysed. 
TABLE I. Effect of heparin and protamine 
Samples or buffer Heparin Protamine sul- Clotting time fate 
Tris-saline 0 U" 0 /lgb 32'· sec 
0.02 0 90 
0.02 2.5 32 
Extract 1 0 0 65 
0 2.5 66 
from TI 5 wk inf. 0.0002 0 65 
Extract 2 0 0 62 
0 2.5 62 
from TI 5 wk inf. 0.0002 0 63 
"United States Pharmacopoeia (USP) units given in 0.6 ml of 
reaction mixture. 
/, Dose in 0.6 ml of reaction mixture. 
,. Mean of duplicated measurements. 
Vol. 73, No_ 6 
The time to lyse the clot was measured. Control lysis time was 25 min 
when tris-saline was used in place of the tissue extracts. Relative 
inhibitor activity was obtained for each sample by comparing the dose-
response curve to that of a noninfected mouse sample in a range where 
the lines appeared parallel [17]. In some cases, further comparison was 
made using 2 or 4 times concentrated tissue extracts, since small 
differences between prolonged lysis times, if they occur, are more 
readily detected at higher concentrations (Fig I). 
RESULTS 
Throughout the entire study the findings made in LM, both 
infected and noninfected were essentially the same as those of 
TI; thus this report contains only results studied with TI and 
AT. 
Immunofluorescence Study 
Monospecific anti-Fib serum reacted with vessel walls but no 
other areas in livers of noninfected TI mice (Fig 2A). After 6 
weeks of infection, the area of fluorescence appeared around 
vessels (Fig 2B). At this time sections stained with H&E re-
vealed perivascular infLitrations of eosinophils, monocytes and 
occasional polymorphonuclear leukocytes, but no granuloma 
had yet been organized though some eggs began to appear in 
venules. At 7 to 8 weeks after infection localized areas reacted 
strongly with anti-Fib (2C). These regions coincided with egg 
granulomas where macrophages had accumulated. Eosinophils 
and plasma cells also were found in and around the granulomas. 
At 10 weeks after infection, however, the immunoreactivity was 
seen only at the margins of granulomas, indicating that depos-
ited fibrin had cleared as the granulomas enlarged and matured 
(Fig 2D). At this time macrophages appeared to be more 
differentiated and some epithelioid cells were found . After that, 
the granuloma tended to diminish in size as healing took pla~e. 
In AT mice similar immunoreactivity was seen in vessel walls 
before infection (Fig 2E) . By 5 and 6 weeks after infection, 
fluorescence was found more diffusely around the vessels and 
massive immunoreactivity often was observed in adjacent areas 
of liver (Fig 2FJ. Preparation stained by H&E, in contrast, 
revealed less inflammatory response perivascularly than ob-
served in TI mice. Polymorphonuclear leukocytes were domi-
nant and no eosinophils were observed. After 7 to 8 weeks of 
infection immunoreactivity was positive over granulomas and 
at their edges; the demarcation was not clear. Fibrin was seen 
in wider areas, although the granuloma itself was much smaller 
than that ofTI (Fig 2G). Unlike TI mice, fluorescence appeared 
to increase progressively with time in granulomatous regions, 
and never showed concentric lysis in the center (Fig 2H). The 
granulomas in AT mice consisted of macro phages as well, but 
less organization of epithelioid cells was found and no eosinophil 
infiltration was observed. 
Thrombin Inhibitor Activity (Table II) 
Control, noninfected TI mice contained thrombin inhibitor 
activity in the hepatic tisssue extracts of 1.80 ± 0.11 NIH UI 
mi. Inhibitor activity significantly increased at 4 to 6 weeks 
after infection (P < 0.026) though the variation was large. After 
8 weeks it began to decrease. Tissue extracts prepared from 
mice 10 weeks or longer after infection showed half the value of 
control animals (P ::S 0.0011). 
AT mice also demonstrated an increase in the inhibitor 
activity after 4 to 6 weeks of infection (p < 0.047), and continue 
to increase at 8 weeks, containing twice the activity of nonin-
fected mice (p::s 0.0011). Even after 10 weeks it did not decrease 
below the normal value. 
Fibrinolysis Inhibitor Activity (Table III) 
In TI mice inhibitor activity decreased slightly by 4 to 6 
weeks after infection and then gradually increased. After 9 to 
10 weeks of infection, strong inhibition, over three times greater 
than control value (P < 8 X 10-8), was detected. Noninfected 
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FIG 1. Effects of tis ue extracts on clot lysis time. A and B, 1'1 mice at 9 weeks after infection; C, 1'1 mice at 7 weeks; D, noninfected 1'1 mouse; 
E, noninfected AT mouse; F and G, infected AT mice for 9 weeks. 
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AT mice showed about the same level of inhibitor activity as 
seen in noninfected TI mice. After infection the activity de-
creased slightly and then returned to normal levels by 7 or 8 
weeks after infection. Increased activity was not observed at 
any time period studied. There still was no difference in lysis 
time between liver extracts of control AT mice and 9 weeks 
after infection, even though the extracts were concentrated 2-
to 4-fold. 
DISCUSSION 
Fibrin deposition was demonstrated to precede granuloma 
formation in murine schistosomiasis. This finding indicates that 
activation of the clotting system takes place in the initial stages 
of chronic granulomatous inflammation as seen in other types 
of inflammatory reactions [3-7]. The fibrin deposition occurred 
not only in TI mice but also in AT mice; the phenomenon thus 
appears to be independent from T-cell function. Since increase 
in tissue fibrin occurred along with enlargement of granulomas 
by 8 weeks after infection, the fibrin may have contributed in 
invasion of cells around the eggs as suggested by Astrup [9]. 
Recently, a tissue factor with procoagulant activity from white 
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TABLE II. Thrombin inhibitor activity" in hepatic tissue extracts 
after schistosome infection 
Infected 
Mice Noninfected 
4-6w 8w lOw or longer 
Thymus 1.80 ± 0.11 2.38 ± 0.56 1.5B ± 0.12 0.97 ± 0.26 
intact (n = 6) (n = 11) (n = 6) (n = 5) 
Athymic 1.65 ± 0.12 2.15 ± 0.46 3.08 ± 0.63 1.64 ± 0.10 
(n = 5) (n = 5) (n = 5) (n = 5) 
" Activity (mean ± standard deviation) is expressed by thrombin 
units (NIH) inhibited per 1 ml of extracts measured in clotting time 
method. 
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blood cells, especially monocytes, was reported [21 , 22] and 
suppression of synthesis of this factor by cycloheximidine led 
to the inhibition of disseminated intravascular coagulation after 
endotoxin injection [23]. In this study, monocytes accumulating 
around the eggs may participate in further activation of the 
clotting system. van Ginkel et al [24] demonstrated stimulation 
of procoagulant activity of monocytes by adherence to glass 
surface. Coagulation promoted by monocytes, therefore, might 
positively feedback, aiding further cellular invasion. 
Thrombin inhibitor activity increased with fibrin deposition 
in the liver. A possibility that heparin derived from mast cells 
showed antithrombin activity was considered [25,26]. However, 
mast cells are absent in granulomas of AT mice [18]. Moreover, 
neither protamine sulphate nor small doses of heparin changed 
the clotting time, suggesting that significant contamination with 
heparin and serum antithrombin III did not occur in the ex-
tracts. Another possibility is that early products of FDP (fibrin-
ogen/fibrin degradation products) may be responsible for 
thrombin inhibitor activity [27]. However, the secondary effect 
of fibrinolysis is less likely to occur because the time when 
antithrombin activity increased did not correspond to the time 
of fibrin clearing. 
Concentric fibrinolysis was observed within t he granuloma of 
TI mice. Since this clearing did not occur in AT mice, fibrino-
lysis proba bly was not caused by plasminogen activator of 
endothelial cells [10,11] or enzymes of polymorphonuclear cells 
[16]. Basophil plasminogen activator [12] also is excluded as 
mice, unlike guinea pigs, do not have this type of leukocyte 
[18]. It seems most likely that the fibrinolysis is initiated by the 
release of macrophage of plasminogen activator under thymo-
cyte stimulation [14,15]. Furthermore, eosinophil granules con-
tain plasminogen [28,29]. Large numbers of eosinophils foun d 
in granulomas of TI mice may facilitate enhancement of local 
fibrinolysis. Although mast cells ruso are found only in TI mice 
[18], the effects of their proteases on plasminogen activation or 
fibrin digestion is controversial [30]. 
Activation of fibrinolysis has several consequences for inflam-
mation. Small molecular weight FDP increase vascular perme-
ability [31], cause peripheral vessel dilatation [32] and decrease 
'lH-thymidine incorporation of lymphocytes [33]. Unidentified 
FDP and fiibrinopeptide B also are chemotactic for monocytes 
[8]. Further, plasmin activates a kinin forming system by at-
tacking H ageman factor [2]. It is possible therefore that fibri-
nolysis and its products help modulate the full expression of 
granulomatous inflammation in TI mice while their absence in 
A T mice contributes to incomplete granuloma formation. 
Kwaan and Astrup showed in their experimental clot system 
that inhibition of fibrinolysis led to increased collagen produc-
tion,presumably on the fibrin meshw.ork [34]. In AT mice, this 
might also account for impaired cellularity of the granulomas 
and increased fibrosis. 
Fibrinolysis inhibitor activity increased only in TI mice, 
suggesting that interplay between proteinases and their inhibi-
tors is involved in regulation of the hepatic lesions. A tissue 
culture study showed that various cells, including lung, kidney, 
heart, bladder, skin, muscle and blood vessels, produce inhibi-
tors of fibrinolysis [35]. Although the cellular origin of the 
inhibitor measured in the present study was not investigated, 
TABLE III. Fibrinolysis inhibitor activity" in hepatic tissue extracts after schistosome infection 
Infected 
Mice Noninfected 
4-6w 7-Bw 9-JOw II-1 2w 
Thymus intact 1.00 ± 0.05 0.79 ± 0.14 2.23 ± 0.88 3.05 ± 0.55 3.68 ± 0.61 
(n = 6) (n = 10) (n = 9) (n = 13) (n = II) 
Athymic 0.93 ± 0.11 0.77 ± 0.04 0.93 0.95 ± 0.12 N.D" 
(n = 5) (n = 3) (n = 1) (n = 6) 
" Activity (mean ± standard deviation) is expressed by a relative inhibitor activity compared to noninfected thymus intact mice when assayed 
in a clot lysis time system. 
" Not determined. 
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production of the inhibitor appears to be: (1) T-cell dependent 
and (2) occurrence in cells at the peripheral area of granulomas. 
Most previous studies have focused on the degree of fibrin 
deposition at a given t ime during inflammation, and have 
attempted to correlate this with prognosis for healing. The 
present study, in contrast, investigated activation of coagulation 
a nd fibrinolysis processes through the course of granulomatous 
inflammation. Detection of fibrin deposit ion and quantification 
of proteinase inhibitors revealed sequential enzymatic interac-
tions as granulomatous lesions formed and healed. The findings 
s uggest that a similar relationship may exist in other inflam-
matory processes in the skin if they are studied in similar detail. 
T his study also elucidated the role of T-cell function in these 
enzymatic activities in situ. It was found that fibrin deposition 
is rather a nonspecific tissue reaction but its clearing is T -cell 
dependent. 
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